MME and heart failure: After the publication of the Prospective comparison of angiotensin receptor-neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) to determine the Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial [6], sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), was added to the guidelines for treating HFrEF.